Augusto Villanueva, Medical Director of the Liver Cancer Program at NYU Langone Health, shared on LinkedIn:
“Tumors don’t age the same way patients do.
Our new study in NPJ Precision Oncology reveals that hepatocellular carcinoma (HCC) tumors have distinct epigenetic ‘ages’, and older tumors predict better patient survival.
Title: Intra-tumoral epigenetic heterogeneity and aberrant molecular clocks in hepatocellular carcinoma
Authors: Paula Restrepo, Adrian Bubie, Amanda J. Craig, Javier Rodriguez Hernaez, Daniel Cameron, Ismail Labgaa, Myron Schwartz, Gustavo Stolovitzky, Bojan Losic, Augusto Villanueva.
Read The Full Article.
We report how DNA methylation patterns at promoters and enhancers reveal a hidden layer of tumor heterogeneity that RNA sequencing alone misses.
This opens a new angle for HCC prognosis and potentially for predicting who might benefit from immune-based therapies.
Beyond the science, it has been great to work with such an awesome team of very talented people!”
You can also read: Hepatocellular Carcinoma and Viral Hepatitis: How HBV and HCV Drive Liver Cancer
